Vascular incontinence: Incontinence in the elderly due to ischemic white matter changes

Neurology International

Volumn 4, Issue 2, 2012, Pages 52-59

  Sakakibara, Ryuji ^a   Panicker, Jalesh ^b   Fowler, Clare J ^b   Tateno, Fuyuki ^a   Kishi, Masahiko ^a   Tsuyuzaki, Yohei ^a   Ogawa, Emina ^a   Uchiyama, Tomoyuki ^c   Yamamoto, Tatsuya ^c  

^a TOHO UNIVERSITY   (Japan)

^b NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^c CHIBA UNIVERSITY   (Japan)

Author keywords

Geriatric incontinence; Overactive bladder; Vascular incontinence; White matter change

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; IMIDAFENACIN; OXYBUTYNIN; PROPIVERINE; SOLIFENACIN; TOLTERODINE;

BLADDER DYSFUNCTION; BLADDER FUNCTION; BLOOD BRAIN BARRIER; BRAIN DISEASE; CONSTIPATION; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG SAFETY; HUMAN; INCONTINENCE; MINI MENTAL STATE EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGICAL ANATOMY; REVIEW; RISK FACTOR; TREATMENT INDICATION; URINARY URGENCY; URINE INCONTINENCE; VASCULAR INCONTINENCE; WHITE MATTER DISEASE; XEROSTOMIA;

EID: 84869821902     PISSN: 20358385     EISSN: 20358377     Source Type: Journal    
DOI: 10.4081/ni.2012.e13     Document Type: Review

References (99)

1. Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU International 2001;87:760-6.
2. Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003;20:327-36.
3. Homma Y, Yamaguchi O, Hayashi K; the Members of the Neurogenic Bladder Society Committee. An epidemiological survey of overactive bladder symptoms in Japan. BJU International 2005;96:1314-8.
4. Irwin DE, Milsom I, Kopp Z, et al. Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries. BJU International 2005;97:96-100.
5. Resnick NM. Urinary incontinence. Lancet 1995;346:94-9.
6. Rosenberg LJ, Griffiths DJ, Resnick NM. Factors that distinguish continent from incontinent older adults with detrusor overactivity. J Urol 2005;174:1868-72.
7. Elbadawi A, Hailemariam S, Yalla SV, Resnick NM. Structural basis of geriatric voiding dysfunction. VII. Prospective ultrastructural/ urodynamic evaluation of its natural evolution. J Urol 1997;157:1814-22.
8. Elbadawi A, Hailemariam S, Yalla SV, Resnick NM. Structural basis of geriatric voiding dysfunction. VI. Validation and update of diagnostic criteria in 71 detrusor biopsies. J Urol. 1997;157:1802-13.
9. Elbadawi A, Yalla SV, Resnick NM. Structural basis of geriatric voiding dysfunction. IV. Bladder outlet obstruction. J Urol 1993;150:1681-95.
10. Elbadawi A, Yalla SV, Resnick NM. Structural basis of geriatric voiding dysfunction. III. Detrusor overactivity. J Urol 1993;150:1668-80.
11. Elbadawi A, Yalla SV, Resnick NM. Structural basis of geriatric voiding dysfunction. II. Aging detrusor: normal versus impaired contractility. J Urol 1993;150: 1657-67.
12. Elbadawi A, Yalla SV, Resnick NM. Structural basis of geriatric voiding dysfunction. I. Methods of a prospective ultrastructural/ urodynamic study and an overview of the findings. J Urol 1993;150: 1650-6.
13. Sakakibara R, Hattori T, Uchiyama T, Yamanishi T. Urinary function in the elderly with and without leukoaraiosis; in relation to cognitive and gait function. J Neurol Neurosurg Psychiatry 1999;67:658-60.
14. Werring DJ, Frazer DW, Coward LJ, et al. Cognitive dysfunction in patients with cerebral microbleeds on T2*-weighted gradient-echo MRI. Brain 2004;127:2265-75.
15. Brant-Zawadzki M, Fein G, Van Dyke C, et al. MR imaging of the aging brain; pacthy white-matter lesions and dementia. AJNR 1985;6:675-82.
16. Roman GC. On the history of lacunes, etat criblé, and the white matter lesions of vascular dementia. Cerebrovasc Dis 2002;13: 1-6.
17. Binswanger O. Die Abgrenzung der allgemeinen progressiven Paralyse. Berl Klin Wochenschr 1894;31:1103-86.
18. Hachinski VC, Potter P, Merskey H. Leukoaraiosis. Arch Neurol 1987;44:21-3.
19. Fazekas F, Schmidt R, Kleinert R, et al. The spectrum of age-associated brain abnormalities: their measurement and histopathological correlates. J Neural Transm Suppl 1998;53:31-9.
20. Enzinger C, Fazekas F, Ropele S, Schmidt R. Progression of cerebral white matter lesions-Clinical and radiological considerations. J Neurol Sci 2007;257:5-10.
21. de Leeuw FE, de Groot JC, Oudkerk M, et al. Hypertension and cerebral white matter lesions in a prospective cohort study. Brain 2002;125:765-72.
22. Sierra C, de La Sierra A, Mercader J, et al. Silent cerebral white matter lesions in middle-aged essential hypertensive patients. J Hypertension 2002;20:519-24.
23. van Dijk EJ, Breteler MMB, Schmidt R, et al; for the CASCADE Consortium. The association between blood pressure, hypertension, and cerebral white matter lesions cardiovascular determinants of dementia study. Hypertension 2004;44: 625-30.
24. Erkinjuntti T, Gauthier S. The concept of vascular cognitive impairment. Front Neurol Neurosci 2009;24:79-85.
25. Wade J, Hachinski V. Revised ischemic score for diagnosing multi-infarct dementia. J Clin Psychiatry 1986;47:437-8.
26. Rektor I, Rektorova I, Kubova D. Vascular parkinsonism-an update. J Neurol Sci 2006; 248:185-91.
27. Kuchel GA, Moscufo N, Guttmann CR, et al. Localization of brain white matter hyperintensities and urinary incontinence in community-dwelling older adults. J Gerontol A Biol Sci Med Sci 2009;64:902-9.
28. Tadic SD, Griffiths D, Murrin A, et al. Brain activity during bladder filling is related to white matter structural changes in older women with urinary incontinence. Neuroscience 2010;51:1294-302.
29. Mazighi M, Labreuche J, Gongora-Rivera F, Duyckaerts C, Hauw JJ, Amarenco JP. Autopsy prevalence of intracranial atherosclerosis in patients with fatal stroke. Stroke 2008;39:1142-7.
30. Wardlaw JM. Blood-brain barrier and cerebral small vessel disease. J Neurol Sci 2010;299: 66-71.
31. Falcao ALE, Reutens DC, Markus R, et al. The resistance to ischemia of white and gray matter after stroke. Ann Neurol 2004;56:695-701.
32. Lee ST, Scott AM. Hypoxia positron emission tomography imaging with 18F-fluoromisonidazole. Semin Nucl Med 2007;37: 451-61.
33. Patterson AJ, U-King-Im JM, Tang TY, et al. Association between white matter ischaemia and carotid plaque morphology as defined by high-resolution in vivo MRI. Eur J Vasc Endovasc Surg 2009;38:149-54.
34. Verpillat P, Alpérovitch A, Cambien F, et al. Aldosterone synthase (CYP11B2) gene polymorphism and cerebral white matter hyperintensities. Neurology 2001;56:673-5.
35. Henskens LH, Kroon AA, van Boxtel MP, et al. Associations of the angiotensin II type 1 receptor A1166C and the endothelial NO synthase G894T gene polymorphisms with silent subcortical white matter lesions in essential hypertension. Stroke 2005;36: 1869-73.
36. Purandare N, Oude Voshaar RC, Davidson Y, et al. Deletion/insertion polymorphism of the angiotensin-converting enzyme gene and white matter hyperintensities in dementia: A pilot study. J Am Geriatr Soc 2006;54:1395-400.
37. Kohara K, Fujisawa M, Ando F, et al; NILSLSA Study. MTHFR gene polymorphism as a risk factor for silent brain infarcts and white matter lesions in the Japanese general population: The NILS-LSA Study. Stroke 2003;34:1130-5.
38. Fornage M, Mosley TH, Jack CR, et al. Family-based association study of matrix metalloproteinase-3 and-9 haplotypes with susceptibility to ischemic white matter injury. Hum Genet 2007;120:671-80.
39. van Oijen M, Cheung EY, Geluk CE, et al. Haplotypes of the fibrinogen gene and cerebral small vessel disease: the Rotterdam scan study. J Neurol Neurosurg Psychiatry 2008;79:799-803.
40. Schmidt R, Schmidt H, Fazekas F, et al. Apolipoprotein E polymorphism and silent microangiopathy-related cerebral damage. Results of the Austrian Stroke Prevention Study. Stroke 1997;28:951-6.
41. Schmidt R, Schmidt H, Fazekas F, et al. MRI cerebral white matter lesions and paraoxonase PON1 polymorphisms: threeyear follow-up of the austrian stroke prevention study. Arterioscler Thromb Vasc Biol 2000;20:1811-6.
42. Reitz C, Berger K, de Maat MP, et al. CRP gene haplotypes, serum CRP, and cerebral small-vessel disease: the Rotterdam Scan Study and the MEMO Study. Stroke 2007; 38:2356-9.
43. Joutel A, Corpechot C, Ducros A, et al. Notch3 mutations in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), a mendelian condition causing stroke and vascular dementia. Ann NY Acad Sci 1997;826:213-7.
44. Hara K, Shiga A, Fukutake T, et al. Association of HTRA1 mutations and familial ischemic cerebral small-vessel disease. New Eng J Med 2009;360:1729-39.
45. Moseley ME, Nishimura MC, Pitts LH, et al. Proton nuclear magnetic resonance spectroscopy of normal and edematous brain tissue in vitro: changes in relaxation during tissue storage. Magn Reson Imaging 1984;2:205-9.
46. Wallin A, Sjogren M, Edman A, et al. Symptoms, vascular risk factors and bloodbrain barrier function in relation to CT white-matter changes in dementia. Eur Neurol 2000;44:229-35.
47. Pantoni L. Pathophysiology of age-related cerebral white matter changes. Cerebrovasc Dis 2002;13:7-10.
48. Sachdev P, Wen W, Chen X, Brodaty H. Progression of white matter hyperintensities in elderly individuals over 3 years. Neurology 2007;68;214-22.
49. Enzinger C, Fazekas F, Ropele S, Schmidt R. Progression of cerebral white matter lesions-clinical and radiological considerations. J Neurol Sci 2007;257:5-10.
50. Gouw AA, van der Flier WM, Fazekas F, et al; LADIS Study Group. Progression of white matter hyperintensities and incidence of new lacunes over a 3-year period: the Leukoaraiosis and Disability study. Stroke 2008;39:1414-20.
51. Rost NS, Fitzpatrick K, Biffi A, et al. White matter hyperintensity burden and susceptibility to cerebral ischemia. Stroke 2010;41:2807-11.
52. Rost NS, Rahman RM, Biffi A, et al. White matter hyperintensity volume is increased in small vessel stroke subtypes. Neurology 2010;75:1670-7.
53. Wardlaw JM, Lewis SC, Keir SL, et al. Cerebral microbleeds are associated with lacunar stroke defined clinically and radiologically, independently of white matter lesions. Stroke 2006;37:2633-6.
54. Tatsumi S, Shinohara M, Yamamoto T. Direct comparison of histology of microbleeds with postmortem MR images a case report. Cerebrovasc Dis 2008;26:142-6.
55. Sakakibara R, Hattori T, Tojo M. Micturitional disturbance in patients with cerebrovascular dementia. Autonom Nerv Syst 1993;30:390-6.
56. Sakakibara R, Hattori T, Yasuda K, Yamanishi T. Micturitional disturbance after acute hemispheric stroke: analysis of the lesion site by CT and MRI. JNeurol Sci 1996;137:47-56.
57. Abrams P, Cardozo L, Fall M, et al; Standardisation Sub-committee of the International Continence Society. The standardization of terminology of lower urinary tract function: report from the standardization sub-committee of the International Continence Society. Neurourol Urodynam 2002;21:167-78.
58. Andrew J, Nathan PW. Lesions of the anterior frontal lobes and disturbances of micturition and defaecation. Brain 1964;87: 233-62.
59. DasGupta R, Kavia RB, Fowler CJ. Cerebral mechanisms and voiding function. BJU Int 2007;99:731-4.
60. Sakakibara R, Tsunoyama K, Takahashi O, et al. Real-time measurement of oxyhemoglobin concentration changes in the frontal micturition area: an fNIRS study. Neurourol Urodyn 2010;29:757-64.
61. Fowler CJ, Griffiths DJ. A decade of functional brain imaging applied to bladder control. Neurourol Urodyn 2010;29:49-55.
62. Herzog J, Weiss PH, Assmus A, et al. Improved sensory gating of urinary bladder afferents in Parkinson's disease following subthalamic stimulation. Brain 2008;131:132-45.
63. Fowler CJ, Griffiths D, de Groat WC. The neural control of micturition. Nat Rev Neurosci 2008;9:453-66.
64. Griffiths D, Tadic SD. Bladder control, urgency, and urge incontinence: evidence from functional brain imaging. Neurourol Urodyn 2008;27:466-74.
65. Hentschel F, Damian M, Krumm B, Froelich L. White matter lesions-ageadjusted values for cognitively healthy and demented subjects. Acta Neurol Scand 2007;115:174-80.
66. Mok V, Wong KK, Xiong Y, Wong A, Schmidt R, Chu W, Hu X, Leung EY, Chen S, Chen Y, Tang WK, Chen X, Ho CL, et al. Cortical and frontal atrophy are associated with cognitive impairment in age-related confluent white-matter lesion. J Neurol Neurosurg Psychiatry 2011;82:52-7.
67. Tullberg M, Fletcher E, DeCarli C, et al. White matter lesions impair frontal lobe function regardless of their location. Neurology 2004;63:246-53.
68. Schuff N, Capizzano AA, Du AT, et al. Different patterns of N-acetylaspartate loss in subcortical ischemic vascular dementia and AD. Neurology 2003;61:358-64.
69. Hanyu H, Shimuzu S, Tanaka Y, et al. Cerebral blood flow patterns in Binswanger's disease: a SPECT study using three-dimensional stereotactic surface projections. J Neurol Sci 2004;220:79-84.
70. Baloh RW, Yue Q, Socotch TM, Jacobson KM. White matter lesions and dysequilibrium in older people; 2. clinicopathological correlation. Arch Neurol 1995;52:975-81.
71. Yamanouchi H, Nagura H. Neurological signs and frontal white matter lesions in vascular parkinsonism. A clinicopathologic study. Stroke 1997;28:965-9.
72. Mok VC, Wong A, Yim P, et al. The validity and reliability of chinese frontal assessment battery in evaluating executive dysfunction among Chinese patients with small subcortical infarct. Alzheimer Dis Assoc Disord 2004;18:68-74.
73. Mok VC, Wong A, Wong K, et al. Executive dysfunction and left frontal white matter hyperintensities are correlated with neuropsychiatric symptoms in stroke patients with confluent white matter hyperintensities. Dement Geriatr Cogn Disord 2010;30: 254-60.
74. Wakefield DB, Moscufo N, Guttmann CR, et al. White matter hyperintensities predict functional decline in voiding, mobility, and cognition in older adults. J Am Geriatr Soc 2010;58:275-81.
75. Gormley EA, Griffiths DJ, McCracken PN, et al. Effect of transurethral resection of the prostate on detrusor instability and urge incontinence in elderly males. Neurourol Urodyn 1993;12:445-53.
76. Gormley EA, Griffiths DJ, McCracken PN, et al. Effect of transurethral resection of the prostate on detrusor instability and urge incontinence in elderly males. Neurourol Urodyn 1993;12:445-53.
77. Sakakibara R, Hamano S, Uchiyama T, et al. Do BPH patients have neurogenic detrusor dysfunction? A uro-neurological assessment. Urol Int 2005;74:44-50.
78. Yamaguchi C, Sakakibara R, Uchiyama T, et al. Overactive bladder in diabetes: a peripheral or central mechanism? Neurourol Urodyn 2007;26:807-13.
79. Kaplan SA, Te AE, Blaivas JG. Urodynamic findings in patients with diabetic cystopathy. J Urol 1995;153:342-4.
80. Rapidi CA, Karadreas N, Katsifotis C, et al. A combined urodynamic and electrophysiological study of diabetic cystopathy. Neurourol Urodynam 2005;24:1-7.
81. Adams RD, Fisher CM, Hakim S, et al. Symptomatic occult hydrocephalus with 'normal' cerebrospinal pressure. N Eng J Med 1965;273:117-26.
82. Hiraoka K, Meguro K, Mori E. Prevalence of idiopathic normal-pressure hydrocephalus in the elderly population of a Japanese rural community. Neurol Med Chir 2008;48:197-9.
83. Sakakibara R, Kanda T, Sekido T, et al. Mechanism of bladder dysfunction in idiopathic normal pressure hydrocephalus. Neurourol Urodyn 2008;27:507-10.
84. Sasaki H, Ishii K, Kono A, et al. Cerebral perfusion pattern of idiopathic normal pressure hydrocephalus studied by SPECT and statistical brain mapping. Ann Nucl Med 2007;21:39-45.
85. Sugiyama T, Hashimoto K, Kiwamoto H, et al. Urinary incontinence in senile dementia of the Alzheimer type (SDAT). Int J Urol 1994;1:337-40.
86. Sakakibara R, Uchiyama T, Yamanishi T, Kishi M. Genitourinary dysfunction in Parkinson's disease. Mov Disord 2010;25: 2-12.
87. Sakakibara R, Ito T, Uchiyama T, et al. Lower urinary tract function in dementia of Lewy body type (DLB). J Neurol Neurosurg Psychiatry 2005;76:729-32.
88. Sakakibara R, Hattori T, Tojo M, et al. Micturitional disturbance in progressive supranuclear palsy. J Auton Nerv Syst 1993;45:101-6.
89. Nagai M, Hoshide S, Kario K. Hypertension and dementia. Am J Hypertens 2010;23:116-24.
90. Duron E, Hanon O. Vascular risk factors, cognitve decline, and dementia. Vascular Health and Risk Management 2008:4:363-81.
91. Cukierman-Yaffe T, Gerstein HC, Williamson JD, et al; ACCORDMIND Investigators. Relationship between baseline glycemic control and cognitive function in individuals with type 2 diabetes and other cardiovascular risk factors. The Action to Control Cardiovascular Risk in Diabetes-Memory in Diabetes (ACCORDMIND) trial. Diabetes Care 2009;32:221-6.
92. Gregoire SM, Jager HR, Yousry TA, et al. Brain microbleeds as a potential risk factor for antiplatelet-related intracerebral haemorrhage: hospital-based, case-control study. J Neurol Neurosurg Psychiatry 2010;81:679-84.
93. Borroni B, Tiberio G, Bonardelli S, et al. Is mild vascular cognitive impairment reversible? Evidence from a study on the effect of carotid endarterectomy. Neurol Res 2004;26:594-7.
94. Lapchak PA. A critical assessment of edaravone acute ischemic stroke efficacy trials: is edaravone an effective neuroprotective therapy? Expert Opin 2010;11:1753-63.
95. Homma Y, Yamaguchi O; for the Imidafenacin Study Group. A randomized, double-blind, placebo-and propiverinecontrolled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder. Int J Urol 2009;16:499-506.
96. Mori S, Kojima M, Sakai Y, Nakajima K. Bladder dysfunction in dementia patients showing urinary incontinence; evaluation with cystometry and treatment with propiverine hydrochloride. Jpn J Geriat 1999;36:489-94.
97. Scheife R, Takeda M. Central nervous system safety of anticholinergic drugs for the treatment of overactive bladder in the elderly. Clin Ther 2005;27:144-53.
98. Sakakibara R, Uchiyama T, Yamanishi T, Kishi M. Dementia and lower urinary dysfunction: with a reference to anticholinergic use in elderly population. Int J Urol 2008;15:778-88.
99. Chu FM, Dmochowski RR, Lama DJ, et al. Extended-release formulations of oxybutynin and tolterodine exhibit similar central nervous system tolerability profiles: A subanalysis of data from the OPERA trial. Am J Obstet Gynecol 2005;192:1849-55.